PDS Biotechnology (NASDAQ:PDSB) Trading Down 8.8%

PDS Biotechnology Co. (NASDAQ:PDSB) shares were down 8.8% on Friday . The stock traded as low as $2.59 and last traded at $2.65. Approximately 881,240 shares were traded during trading, a decline of 0% from the average daily volume of 884,327 shares. The stock had previously closed at $2.90.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PDSB shares. B. Riley reissued a “buy” rating and set a $11.00 price objective (down from $14.00) on shares of PDS Biotechnology in a research note on Thursday, March 28th. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a research note on Wednesday, March 27th. StockNews.com lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, March 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of PDS Biotechnology in a research note on Friday, January 12th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, PDS Biotechnology has an average rating of “Moderate Buy” and an average price target of $17.33.

PDS Biotechnology Trading Down 8.8 %

The firm has a market cap of $97.02 million, a price-to-earnings ratio of -1.92 and a beta of 1.67. The company has a 50-day moving average price of $4.61 and a 200 day moving average price of $4.87. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.75.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, March 27th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.05. As a group, research analysts anticipate that PDS Biotechnology Co. will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth $45,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of PDS Biotechnology during the third quarter worth $30,000. Cary Street Partners Investment Advisory LLC raised its holdings in shares of PDS Biotechnology by 187.7% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 6,131 shares of the company’s stock worth $31,000 after acquiring an additional 4,000 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in shares of PDS Biotechnology during the first quarter worth $28,000. Finally, BNP Paribas Arbitrage SNC purchased a new stake in shares of PDS Biotechnology during the second quarter worth $37,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.